Polymyxin B

What is Polymyxin B?

Polymyxin B is an antibiotic that belongs to the polymyxin class of antibiotics, a group of cationic antimicrobial peptides. Originally isolated from the bacterium Bacillus polymyxa in the late 1940s, it has been a crucial agent in the fight against certain types of bacterial infections. While its use declined for a period due to concerns about toxicity and the availability of newer antibiotics, Polymyxin B has experienced a significant resurgence in recent decades. This renewed interest is primarily driven by the global rise of multidrug-resistant (MDR) Gram-negative bacteria, for which treatment options are increasingly limited. It is now often considered a drug of last resort for these challenging pathogens.

How Does it Work?

The mechanism of action of Polymyxin B is distinct and highly effective against its target bacteria. It functions primarily by disrupting the integrity of the bacterial cell membrane. Specifically, Polymyxin B is a polycationic molecule that binds to the anionic lipopolysaccharide (LPS) components found in the outer membrane of Gram-negative bacteria. This binding displaces essential divalent cations (like magnesium and calcium) that stabilize the LPS layer, leading to increased permeability of the outer membrane. Subsequently, Polymyxin B inserts into the inner cytoplasmic membrane, causing a rapid leakage of intracellular contents such as ions, ATP, and nucleic acids. This disruption of the membrane structure and function ultimately leads to bacterial cell death, making Polymyxin B a bactericidal antibiotic.

Medical Uses

Polymyxin B is primarily reserved for severe infections caused by multidrug-resistant Gram-negative bacteria. Its spectrum of activity includes challenging pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, and certain strains of Klebsiella pneumoniae and Enterobacter species. Key medical uses include:

• Systemic Infections: For severe bloodstream infections (bacteremia), pneumonia, meningitis, and complicated urinary tract infections (UTIs) when other less toxic antibiotics are ineffective. It's typically administered intravenously for these conditions.
• Topical and Ophthalmic Infections: Due to its excellent activity against Gram-negative organisms, Polymyxin B is frequently used topically in combination with other antibiotics (e.g., bacitracin, neomycin) for skin infections, minor cuts, and burns. It is also a common component in ophthalmic solutions and ointments for bacterial conjunctivitis and other eye infections, as well as otic preparations for ear infections.
• Inhalation Therapy: In some cases, it may be administered via nebulizer for chronic respiratory infections, particularly in patients with cystic fibrosis who suffer from recurrent Pseudomonas aeruginosa infections.

Dosage

The dosage of Polymyxin B is highly dependent on the route of administration, the severity and type of infection, and the patient's renal function. Because of its potential for toxicity, careful dosing and monitoring are essential.

• Intravenous (IV) Administration: For systemic infections, typical doses range from 1.5 to 2.5 mg/kg/day (equivalent to 15,000 to 25,000 units/kg/day) divided into two doses. Dosing must be adjusted for patients with impaired kidney function to prevent accumulation and reduce the risk of adverse effects.
• Topical/Ophthalmic/Otic: These formulations are typically applied several times a day as directed by a healthcare professional. Dosing in these forms is generally localized and carries a lower risk of systemic toxicity.
• Intrathecal Administration: In rare cases for meningitis, it may be administered directly into the spinal fluid, requiring highly specialized dosing protocols.

It is crucial for dosage to be determined and monitored by a physician, often in consultation with an infectious disease specialist.

Side Effects

Despite its efficacy, Polymyxin B is associated with significant potential side effects, which were a primary reason for its initial decline in use. The most concerning adverse effects are:

• Nephrotoxicity: This is the most common and serious side effect, involving damage to the kidneys. It can manifest as acute kidney injury, characterized by elevated blood urea nitrogen (BUN) and creatinine levels. Regular monitoring of renal function is mandatory during treatment.
• Neurotoxicity: While less common than nephrotoxicity, neurotoxic effects can occur. These may include paresthesia (tingling or numbness), dizziness, vertigo, ataxia, slurred speech, and blurred vision. In severe cases, neuromuscular blockade leading to respiratory paralysis has been reported, especially with rapid intravenous administration or in patients with pre-existing neuromuscular disorders.
• Allergic Reactions: Skin rashes, itching, and other hypersensitivity reactions can occur, though they are relatively rare.
• Local Irritation: With topical application, some patients may experience localized irritation, redness, or burning.

Drug Interactions

Polymyxin B can interact with several other medications, increasing the risk of adverse effects. Patients should always inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements.

• Nephrotoxic Drugs: Co-administration with other drugs known to cause kidney damage (e.g., aminoglycosides like gentamicin, amphotericin B, NSAIDs, ciclosporin, tacrolimus) can significantly increase the risk and severity of nephrotoxicity.
• Neuromuscular Blocking Agents: Polymyxin B possesses neuromuscular blocking activity. Concurrent use with other neuromuscular blocking agents (e.g., rocuronium, succinylcholine) can potentiate muscle weakness and respiratory depression, necessitating careful monitoring.
• Other Ototoxic Drugs: While less common, co-administration with other drugs that can cause ear damage (ototoxicity) should be approached with caution.

FAQ

Is Polymyxin B a strong antibiotic?

Yes, Polymyxin B is considered a very strong antibiotic, particularly against certain multidrug-resistant Gram-negative bacteria, often serving as a drug of last resort.

What type of bacteria does Polymyxin B kill?

It primarily targets Gram-negative bacteria, including challenging pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, and some strains of Klebsiella pneumoniae and Enterobacter species.

Can Polymyxin B be used for UTIs?

Yes, Polymyxin B can be used for complicated urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacteria, especially when other antibiotics are ineffective.

What are the main risks of Polymyxin B?

The main risks are nephrotoxicity (kidney damage) and neurotoxicity (effects on the nervous system, including potential respiratory paralysis), which require careful monitoring during treatment.

Why is Polymyxin B used less frequently than some other antibiotics?

Historically, its use was limited due to its significant toxicity profile, especially nephrotoxicity. It is now primarily reserved for severe infections where safer alternatives are not effective, acting as a crucial option for multidrug-resistant pathogens.

Products containing Polymyxin B are available through trusted online pharmacies. You can browse Polymyxin B-based medications at ShipperVIP or Medicenter.

Summary

Polymyxin B is a potent, bactericidal antibiotic that plays a vital role in treating severe infections caused by multidrug-resistant Gram-negative bacteria. Its unique mechanism of action, involving the disruption of bacterial cell membranes, makes it effective against pathogens that resist many other antibiotics. While indispensable for certain life-threatening conditions, its use is carefully managed due to potential side effects, primarily nephrotoxicity and neurotoxicity. As a drug of last resort, Polymyxin B underscores the ongoing challenge of antibiotic resistance and the critical need for judicious antimicrobial stewardship.